Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1738752 | 0.98 | OPRM1 (0.49) | OPRM1OPRK1OPRD1OPRL1CA12 | |
| SCHEMBL748761 | 0.95 | OPRM1 (0.50) | OPRM1OPRK1OPRD1OPRL1CA12 | |
| SCHEMBL15573716 | 0.90 | OPRM1 (0.53) | OPRM1OPRK1OPRD1OPRL1CA12 | |
| SCHEMBL12526871 | 0.90 | OPRM1 (0.53) | OPRM1OPRK1OPRD1OPRL1CA12 | |
| SCHEMBL5821025 | 0.90 | OPRM1 (0.44) | OPRM1OPRK1OPRD1OPRL1CA12 | |
| SCHEMBL5751317 | 0.88 | OPRM1 (0.43) | OPRM1OPRK1OPRD1OPRL1CA12 | |
| SCHEMBL20335391 | 0.81 | OPRM1 (0.44) | OPRM1OPRK1OPRD1OPRL1CA12 | |
| SCHEMBL25356567 | 0.80 | OPRM1 (0.46) | OPRM1OPRK1OPRD1OPRL1CA12 | |
| SCHEMBL22448146 | 0.80 | OPRM1 (0.46) | OPRM1OPRK1OPRD1OPRL1CA12 | |
| SCHEMBL4467180 | 0.80 | OPRM1 (0.46) | OPRM1OPRK1OPRD1OPRL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708334-B2 | Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-07-18 | — | — | US | disclosed |
| EP-3134406-A1 | SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044167-A1 | SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE LLC | 2017-02-16 | — | — | US | disclosed |
| WO-2015164520-A1 | SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C] PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C] PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2015-10-29 | — | — | WO | disclosed |
| US-8901152-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| CN-103641823-A | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBVIE INC | 2014-03-19 | — | — | CN | disclosed |
| US-8444877-B2 | High dielectric constant liquid crystal | VVI BRIGHT CHINA LTD. (CN) | 2013-05-21 | — | — | US | disclosed |
| US-8444877-B2 | High dielectric constant liquid crystal | VVI BRIGHT CHINA LTD. (CN) | 2013-05-21 | — | — | US | disclosed |
| US-20120277223-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| US-8242139-B2 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES (US) | 2012-08-14 | — | — | US | disclosed |
| CN-1993323-A | Indole, indazole or indoline derivatives | HOFFMANN LA ROCHE (CH) | 2007-07-04 | — | — | CN | disclosed |
| EP-1768975-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | Pfizer Products Inc. (US) | 2007-04-04 | — | — | EP | disclosed |
| CN-1934081-A | Novel benayl(idene)-lactam derivatives | PFIZER (US) | 2007-03-21 | — | — | CN | disclosed |
| EP-1719746-A1 | OPTICAL RESOLVER, PROCESS FOR PRODUCING OPTICALLY ACTIVE ISOMER, AND 1,5-SUBSTITUTED BICYCLO (3.3.0) -2-OXAOCTANE COMPOUND | ZEON CORPORATION (JP) | 2006-11-08 | — | — | EP | disclosed |
| WO-2006106416-A1 | PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| WO-2006048727-A1 | PIPERAZINYLPHENALKYL LACTAM/AMINE LIGANDS FOR THE 5HT1B RECEPTOR | PFIZER PRODUCTS INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | PFIZER INC | 2006-02-02 | — | — | US | disclosed |
| WO-2006000912-A2 | PYRIDYL PIPERAZINES FOR THE TREATMENT OF CNS DISORDERS | PFIZER PRODUCTS INC. (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | PFIZER INC. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030613-A1 | Indole, indazole and indoline derivatives as CETP inhibitors | CETP, NAT1, MTTP | OPRM1 1881/4885OPRK1 610/4885OPRD1 914/4885 |
| US-20060025421-A1 | Pyridyl piperazines for the treatment of CNS disorders | TPH2, HTR1A, TPH1 | OPRM1 90/4885OPRK1 100/4885OPRD1 69/4885 |
| US-20050245521-A1 | Novel benayl(idene)-lactam derivatives | HTR1E, HTR1D, HTR1A | OPRM1 37/4885OPRK1 22/4885OPRD1 15/4885 |
| US-20120277223-A1 | INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME | DGAT1, DGAT2, LCAT | OPRM1 4091/4885OPRK1 3455/4885OPRD1 2803/4885 |
| US-20170044167-A1 | SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS | GLRA1, GRIA3, GRIA4 | OPRM1 237/4885OPRK1 49/4885OPRD1 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.